Monte Rosa's MRT-8102 Demonstrates 85% Reduction in Cardiovascular Inflammation Marker in Phase 1 Trial
核心洞察
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing an 85% reduction in high-sensitivity C-reactive protein (hsCRP) after four weeks of treatment in subjects with elevated cardiovascular disease (搜索) risk.
The molecular glue degrader achieved rapid and sustained degradation of NEK7 (搜索) protein (80-90%) and significantly reduced inflammatory markers including IL-6 levels by 55% to below cardiovascular risk thresholds.
The company plans to expand the GFORCE-1 study and initiate Phase 2 trials in atherosclerotic cardiovascular disease (搜索) in 2026, while also evaluating the drug for additional inflammatory conditions including MASH (搜索), gout (搜索), and recurrent pericarditis (搜索).
Monte Rosa Therapeutics announced positive interim Phase 1 data for MRT-8102, an investigational molecular glue degrader targeting NEK7 (搜索) for inflammatory diseases. The trial demonstrated significant anti-inflammatory effects in subjects with elevated cardiovascular disease (搜索) risk, with the drug achieving an 85% reduction in high-sensitivity C-reactive protein (hsCRP) after four weeks of treatment.
Strong Anti-Inflammatory Activity Observed
The Phase 1 study (NCT07119125) is a randomized, double-blind, placebo-controlled trial evaluating MRT-8102 in healthy volunteers through single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Part 3 of the study specifically enrolled subjects with increased cardiovascular disease (搜索) risk due to obesity and elevated CRP levels.
In the 24 subjects who completed four weeks of dosing in Part 3, MRT-8102 demonstrated rapid and sustained degradation of NEK7 (搜索) protein in peripheral blood T cells, achieving approximately 80-90% degradation across all dose levels. This mechanism of action led to marked reductions in multiple inflammatory markers.
"Based on the highly encouraging data for MRT-8102 we have observed so far, we are expanding our proof-of-concept GFORCE-1 study in subjects with elevated CVD risk, in order to accelerate the anticipated Phase 2 (GFORCE-2) study of MRT-8102 in ASCVD," said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa Therapeutics.
Cardiovascular Risk Markers Show Dramatic Improvement
The most striking finding was the 85% reduction in hsCRP levels after four weeks of treatment, compared to no significant change in the placebo group. Additionally, 94% of subjects achieved hsCRP suppression to below 2 mg/L, a threshold associated with reduced cardiovascular disease (搜索) risk. The median baseline hsCRP level was 6.3 mg/L.
Beyond CRP reduction, MRT-8102 demonstrated significant effects on other inflammatory pathways. In subjects with high CRP levels across all dose cohorts, endogenous IL-6 levels dropped by a median of 55%, reaching levels below the cardiovascular risk threshold. The drug also led to marked suppression of IL-1β secretion in patients with elevated baseline CRP levels in the multiple ascending dose cohorts.
Central Nervous System Effects Observed
In two subjects with elevated baseline cerebrospinal fluid (CSF) IL-6 levels, MRT-8102 produced a 75% decrease in CSF IL-6. Notably, plasma IL-6 levels were low at baseline in these subjects, potentially suggesting central nervous system-specific effects of the drug.
Favorable Safety Profile
The safety profile observed to date was favorable across all study cohorts. Based on blinded safety data, adverse events were limited in number, mild to moderate in severity, and self-resolving. Importantly, no dose-dependent relationship in frequency or severity of adverse events was observed, and there was no evidence of increased infection risk.
Expanding Development Program
Monte Rosa expects results from the GFORCE-1 study in the second half of 2026 and plans to initiate the Phase 2 GFORCE-2 study of MRT-8102 in atherosclerotic cardiovascular disease (搜索) patients in 2026. The company is also evaluating additional Phase 2 proof-of-concept studies in metabolic dysfunction-associated steatohepatitis (MASH (搜索)), gout (搜索), and recurrent pericarditis (搜索), conditions strongly linked to NLRP3 (搜索) pathway activation.
Mechanism and Therapeutic Potential
MRT-8102 is a potent, highly selective, and orally bioavailable molecular glue degrader that targets NEK7 (搜索) for treatment of inflammatory diseases linked to NLRP3 (搜索), IL-1 (搜索), and IL-6 dysregulation. NEK7 is required for NLRP3 inflammasome assembly, activation, and IL-1β release. Aberrant NLRP3 inflammasome activation has been implicated in multiple inflammatory disorders, including cardiovascular disease (搜索), gout (搜索), osteoarthritis (搜索), asthma (搜索), neurodegenerative diseases, and metabolic disorders.
In non-human primate studies, MRT-8102 demonstrated potent, selective, and durable NEK7 (搜索) degradation, resulting in near-complete reductions of IL-1β and caspase-1 following ex vivo stimulation of whole blood. The drug has shown a considerable safety margin with greater than 200-fold exposure margin over the projected human efficacious dose in GLP toxicology studies.